FDA to Support Potential Use of Real-World Data to Generate Real-World Evidence for Regulatory Decision-Making
The objectives of the new opportunity are to improve the quality and/or use of RWD, promote better understanding of RWE study designs, and develop specific tools to evaluate aspects of RWE generation.
A new funding opportunity from FDA has been established for projects to further promote the potential use of real-world data (RWD) to generate real-world evidence (RWE) related to drug development. FDA hopes to encourage more projects that address these types of gaps in knowledge that can limit the use of RWD and RWE.
The objectives of the new opportunity are to improve the quality and/or use of RWD, promote better understanding of RWE study designs, and develop specific tools to evaluate aspects of RWE generation. FDA encourages a variety of projects that are applicable to drugs and biologics, excluding devices.
To further meet the requirements of the 21st Century Cures Act, FDA developed an RWE Program and subsequently published an RWE Framework and as a series of RWD/RWE draft guidance documents about the use of RWE to assist a new indication for an approved drug or to satisfy post-approval study requirements.
In addition, FDA funded various demonstration projects involving external collaboration and engagements, including four U01 awards in 2020 that analyzed the use of RWD and RWE. The projects are almost complete, and the announcement of this recent funding opportunity emphasizes FDA’s efforts to continue to encourage innovative approaches and improved understanding of RWD and RWE.
Source: FDA Announces New Funding Opportunity to Support the Potential Use of Real-World Data to Generate Real-World Evidence for Regulatory Decision-Making, Press Release, Dec. 15, 2022
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
